# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
LogicBio Therapeutics (NASDAQ:LOGC) reported quarterly losses of $(0.18) per share. This is a 41.94 percent increase over losse...
-SEC Filing
Gainers LogicBio Therapeutics, Inc. (NASDAQ: LOGC) shares surged 637.6% to close at $2.01 on Monday after the company announ...
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite climbing around 270 points on Monday.
Gainers
LogicBio Therapeutics's (NASDAQ:LOGC) short percent of float has fallen 62.5% since its last report. The company recently r...
Gainers LogicBio Therapeutics, Inc. (NASDAQ: LOGC) gained 641% to $2.0207 after the company announced it will be acquired by...
U.S. stocks extended gains midway through trading, with the Dow Jones gaining more than 600 points on Monday.
Gainers LogicBio Therapeutics (NASDAQ:LOGC) shares moved upwards by 641.3% to $2.02 during Monday's pre-market session. ...